CorMedix Inc (CRMD)vsRevolution Medicines Inc (RVMD)
CRMD
CorMedix Inc
$8.36
-2.11%
HEALTHCARE · Cap: $669.98M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
CorMedix Inc generates 53816% more annual revenue ($400.05M vs $742,000). CRMD leads profitability with a 45.3% profit margin vs 0.0%. CRMD earns a higher WallStSmart Score of 80/100 (B+).
CRMD
Strong Buy80
out of 100
Grade: B+
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 41 in profit
Keeps 45 of every $100 in revenue as profit
Strong operational efficiency at 50.0%
Revenue surging 226.1% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CRMD
The strongest argument for CRMD centers on P/E Ratio, Price/Book, Return on Equity. Profitability is solid with margins at 45.3% and operating margin at 50.0%. Revenue growth of 226.1% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : CRMD
The primary concerns for CRMD are Altman Z-Score, Market Cap, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
CRMD profiles as a growth stock while RVMD is a value play — different risk/reward profiles.
CRMD carries more volatility with a beta of 1.47 — expect wider price swings.
CRMD is growing revenue faster at 226.1% — sustainability is the question.
CRMD generates stronger free cash flow (42M), providing more financial flexibility.
Bottom Line
CRMD scores higher overall (80/100 vs 24/100), backed by strong 45.3% margins and 226.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CorMedix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. The company is headquartered in Berkeley Heights, New Jersey.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?